Pharma Blog Watch

Barr Re-Files for Plan B (Eye on FDA)
In his blog, Mark Senak writes that if Andrew von Eschenbach, acting FDA commissioner, were to finally approve Plan B, it would not only prove he can lead the agency, but it would restore credibility to the FDA.

Risk Management Plans (Drug Wonks)
In his entry, blogger Robert Goldberg discusses the problematic risk management plan in place for the acne drug isotretinoin, which can cause birth defects.